ABSTRACT
BACKGROUND AND OBJECTIVES: Our aim was to evaluate the growth-promoting effect of growth hormone (GH) treatment in infants with chronic renal failure (CRF) and persistent growth retardation despite adequate nutritional and metabolic management. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study design included randomized, parallel groups in an open, multicenter trial comparing GH (0.33 mg/kg per wk) with nontreatment with GH during 12 months. Sixteen infants who had growth retardation, were aged 12+/-3 months, had CRF (GFRSubject(s)
Growth Disorders/drug therapy
, Human Growth Hormone/therapeutic use
, Infant Nutritional Physiological Phenomena
, Kidney Failure, Chronic/drug therapy
, Nutritional Status
, Absorptiometry, Photon
, Arm Bones/diagnostic imaging
, Arm Bones/drug effects
, Arm Bones/growth & development
, Biomarkers/blood
, Body Height/drug effects
, Body Weight/drug effects
, Bone Density/drug effects
, Chi-Square Distribution
, Enzyme-Linked Immunosorbent Assay
, Female
, Glomerular Filtration Rate
, Growth Disorders/blood
, Growth Disorders/etiology
, Growth Disorders/physiopathology
, Human Growth Hormone/adverse effects
, Humans
, Infant
, Kidney Failure, Chronic/blood
, Kidney Failure, Chronic/complications
, Kidney Failure, Chronic/physiopathology
, Male
, Portugal
, Prospective Studies
, Radioimmunoassay
, Spain
, Tarsal Bones/diagnostic imaging
, Tarsal Bones/drug effects
, Tarsal Bones/growth & development
, Time Factors
, Treatment Outcome